The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
Subgroup analysis of a confirmatory US study in bladder cancer suggests no benefit in female patients.
With mounting competition in Her2-directed breast cancer treatment, Zymeworks’ latecomer struggles to show that it’s better.
Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.